Your browser doesn't support javascript.
loading
Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis.
Marklund, Matti; Aminde, Leopold N; Wanjau, Mary Njeri; Huang, Liping; Awuor, Celine; Steele, Lindsay; Cobb, Laura K; Veerman, J Lennert; Wu, Jason Hy.
Afiliação
  • Marklund M; Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden matti.marklund@pubcare.uu.se.
  • Aminde LN; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Wanjau MN; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Huang L; Public Health and Economics Modelling Group, School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.
  • Awuor C; Public Health and Economics Modelling Group, School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.
  • Steele L; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Cobb LK; International Institute for Legislative Affairs, Nairobi, Kenya.
  • Veerman JL; Resolve to Save Lives, New York, New York, USA.
  • Wu JH; Resolve to Save Lives, New York, New York, USA.
BMJ Glob Health ; 8(10)2023 10.
Article em En | MEDLINE | ID: mdl-37848268
OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses of observational studies and peer-reviewed evidence of healthcare and policy implementation costs. SETTING: Kenya. PARTICIPANTS: Adults aged ≥20 years at baseline (n=50 million). INTERVENTION: A mandatory iTFA limit (≤2% of all fats) in the Kenyan food supply compared with a base case scenario of maintaining current trans fat intake. MAIN OUTCOME MEASURES: Averted ischaemic heart disease (IHD) events and deaths, health-adjusted life years; healthcare costs; policy implementation costs; net costs; and incremental cost-effectiveness ratio. RESULTS: Over the first 10 years, the intervention was estimated to prevent ~1900 (95% uncertainty interval (UI): 1714; 2148) IHD deaths and ~17 000 (95% UI: 15 475; 19 551) IHD events, and to save ~US$50 million (95% UI: 44; 56). The corresponding estimates over the lifespan of the model population were ~49 000 (95% UI: 43 775; 55 326) IHD deaths prevented, ~113 000 (95% UI: 100 104; 127 969) IHD events prevented and some ~US$300 million (256; 331) saved. Policy implementation costs were estimated as ~US$9 million over the first 10 years and ~US$20 million over the population lifetime. The intervention was estimated to be cost saving regardless of the time horizon. Findings were robust across multiple sensitivity analyses. CONCLUSIONS: Findings support policy action for a mandatory iTFA limit as a cost-saving strategy to avert IHD events and deaths in Kenya.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Graxos trans / Análise de Custo-Efetividade Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Graxos trans / Análise de Custo-Efetividade Idioma: En Ano de publicação: 2023 Tipo de documento: Article